Paying users zone. Data is covered by 
.
Get 1 month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Regeneron Pharmaceuticals Inc. (REGN)
Statement of Financial Position, Assets
Quarterly Data
Difficulty: Beginner
The statement of financial position provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Regeneron Pharmaceuticals Inc., Consolidated Statement of Financial Position, Assets (quarterly data)
US$ in thousands
Based on: 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).
Assets, Selected Items
| Item | Description | The company |
|---|---|---|
| Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Regeneron Pharmaceuticals Inc.’s current assets increased from Q4 2018 to Q1 2019 but then slightly declined from Q1 2019 to Q2 2019 not reaching Q4 2018 level. |
| Property, plant, and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. | Regeneron Pharmaceuticals Inc.’s property, plant, and equipment, net increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Noncurrent assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Regeneron Pharmaceuticals Inc.’s noncurrent assets increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Total assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Regeneron Pharmaceuticals Inc.’s total assets increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
Current Assets, Selected Items
| Item | Description | The company |
|---|---|---|
| Cash and cash equivalents | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. | Regeneron Pharmaceuticals Inc.’s cash and cash equivalents increased from Q4 2018 to Q1 2019 but then declined significantly from Q1 2019 to Q2 2019. |
| Marketable securities | Amount of investment in marketable security, classified as current. | Regeneron Pharmaceuticals Inc.’s marketable securities increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Accounts receivable, trade, net | Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. | Regeneron Pharmaceuticals Inc.’s accounts receivable, trade, net increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Inventories | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. | Regeneron Pharmaceuticals Inc.’s inventories increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |